Managing Partner, Abingworth
Kurt von Emster, CFA
Mr. Kurt von Emster has served on our Board of Directors since April 2015. Kurt currently serves as Managing Partner at Abingworth LLP, where he has been employed as a Partner since January 2015. He also has served as a member of the Board of Directors of SutroVax (where he is currently Chairman) since July 2015 and CymaBay Therapeutics since April 2009. Kurt previously served on the Board of Directors of Kesios Therapeutics, Cytos Biotechnology (merged and renamed Kuros Biosciences), Aurinia Pharmaceuticals, Facet Biotech Corporation (acquired by Abbott Laboratories) and Somaxon Pharmaceuticals (acquired by Pernix Therapeutics). In addition, Kurt co-founded venBio LLC, a healthcare-focused investment firm, in 2009, and served as a Partner until 2014. Prior to that, he was General Partner at MPM Capital, a biotechnology private equity firm, from 2001 to 2009. He received a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst, or CFA.